Revenue is seen going up by 11 percent to Rs 1,620 crore from Rs 1,463.4 crore during the same period. Operating profit may rise 11 percent year-on-year to Rs 348.5 crore but margin may fall marginally to 21.5 percent from 21.6 percent.

Analysis of Glenmark Pharma results

Analysis of Glenmark Pharma results

Glenmark Q3 PAT seen down 14% to Rs 184 cr on high base

Revenues are seen going up 13.2 percent to Rs 1,565 crore in the quarter ended December 2013 from Rs 1,382 crore in a year ago period.

Glenmark Pharma Q3 PAT may dip 23% at Rs 164cr: ICICIdirect

Revenues of Glenmark Pharma are expected to rise by 4.2 percent Q-o-Q (up 10.4 percent Y-o-Y) to Rs 1525.4 crore, according to ICICIdirect.com.

Glenmark Q3 PAT seen down 23% to Rs 164.2cr: PLilladher

The sales of Glenmark Pharma are expected to rise by 4.3 percent Q-o-Q (up 10.5 percent Y-o-Y) to Rs 1526.4 crore, according to Prabhudas Lilladher.

Ranbaxy to drag; buy DRL, Glenmark; neutral on Lupin: Rathi

He is positive on Dr Reddy mainly because the company is going to benefit significantly in FY14 and FY15 from the new launches and at the same time the margins will also be higher. He does not expect any major surprise coming in Lupins' quarterly result.

Glenmark Pharma Q1 PAT seen up 26% at Rs 153 cr: Emkay

Emkay Equity Advisory expects Glenmark Pharma to report a 17.3 percent degrowth quarter-on-quarter (growth of 25.9 percent year-on-year) in net profit at Rs 152.7 crore.

Glenmark Q1 net seen up 89% at Rs 147.6 cr: P Lilladher

Prabhudas Lilladher expects Glenmark Pharma to report a 11.5 percent degrowth quarter-on-quarter (growth of 88.6 percent year-on-year) in net profit at Rs 147.6 crore.

Indian pharmas gain on N America boost: Q4 earnings review

CNBC-TV18‘s Archana Shukla reports that the pharma sector‘s fortunes in the January-March quarter were dictated by the US market while the sector's earnings were mixed.

Ranbaxy Q1 profit likely at Rs 173cr; revenue seen down 31%

Ranbaxy's first quarter net profit is seen at Rs 173 crore, compared with a Rs 1,246 crore profit in the year ago quarter, according to a CNBC-TV18 poll. The results are not really comparable since it got a boost from launch of generic Lipitor last year.

Glenmark: Environment challenging, see 20% growth in FY14

Pharma major Glenmark says the operating environment is challenging given the slowdown in India and longer time taken by the US drug regulator for product approvals. It is expecting a 20 percent revenue growth in FY14.

Glenmark Q4 net profit seen flat at Rs 150cr

Glenmark Pharma is likely to report 16 percent year-on-year growth in fourth quarter revenue at Rs 1,240 crore, whilenet profit is seen flat at Rs 150 crore, according to a CNBC-TV18 poll.

Pharma cos likely to post 21% EBITDA growth in Q4: MOST

Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).

Although robust nos, analysts cautious of Glenmark

Glenmark Pharma reported stronger-than-expected numbers on all parameters as its consolidated net profit grew by 4.6 times year-on-year to Rs 213 crore in the third quarter of financial year 2012-13.

Glenmark Pharma Q3 profit seen up 4 times to Rs 181 cr

Glenmark Pharma is set to declare its results for the third quarter of financial year 2012-13 on Tuesday. Analysts on an average expect profit after tax to grow 4 times year-on-year to Rs 181 crore in the quarter due to EBITDA expansion and one off income.

Good performance likely from pharma in Q3: Nirmal Bang

Nirmal Bang has come out with its earnings estimates for pharmaceutical sector for the quarter ended December 2012. The research firm feels margins of pharma companies may witness YoY expansion owing to rupee depreciation (6 percent YoY).

See pharma sector's Q3 topline to grow 22%: Motilal Oswal

Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.

May not see 35% growth in H1 sustaining in H2: Glenmark

Glenn Saldanha, MD & CEO, Glenmark said the pharma major is growth at the rate of 30% in the Indian market and is confident of maintaining margins ahead.

Glenmark Q2 PAT seen up 158% to Rs 144 cr

Glenmark Pharma is likely to report a profit after tax of Rs 144 crore in the second quarter of FY13, a sharp growth of 158 percent compared to low base of Rs 55.8 crore in a year ago period. In the quarter ended September 2011, the company had recorded mark-to-market foreign exchange loss of Rs 81 crore.

Earnings watch: Which pharma co is in pink of its health?

In an interview to CNBC-TV18 Bino Pathiparampil of IIFL shared his expectation from various pharmaceutical companies ahead for their earnings.

Glenmark Q1 revenues seen up 18% YoY to Rs 1028 cr

Glenmark Pharma is set to declare its results for the quarter ended June 2012 on Thursday. Analysts on an average expect the profit after tax to fall by 37.62% year-on-year and 13.8% quarter-on-quarter to Rs 131 crore during the quarter.

Glenmark Pharma Q1 PAT seen down 38% at Rs 131 cr

Glenmark Pharma is set to declare its results for the quarter ended June 2012 on Thursday. Analysts on an average expect the profit after tax to fall by 37.62% year-on-year and 13.8% quarter-on-quarter to Rs 131 crore during the quarter.

Adj PAT of healthcare sector likely to grow 11% YoY: MOSt

Motilal Oswal expects topline growth of 22% YoY for their Healthcare universe (excluding one-offs), with robust EBITDA growth of 35% YoY. Adjusted PAT is likely to grow 11% YoY, says Motilal Oswal.

Glenmark sees 22-25% sales growth, no acquisitions in FY13

After a strong growth in 2011-12, Glenmark Pharmaceuticals expects to continue strong growth momentum this year too. It expects sales will rise 22-25% (excluding licensing income), helped by new drug launches in the US market and strong growth in most other regions.

Launches in FY13 to boost growth in Indian market: Glenmark

Aided by malarone and cutivate generic, the US business of Glenmark Pharma saw recovery in the fourth quarter of FY12. In an interview with CNBC-TV18, Glenn Saldanha, MD & CEO of Glenmark said, the company expects its domestic market to outperform industry in FY13.